Cost-effectiveness of oral anticoagulants for stroke prevention in atrial fibrillation: a systematic review
Tạp chí Nghiên cứu Dược và Thông tin Thuốc · 19.05.2026
DOI: 10.59882/1859-364x/404 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Tạp chí Nghiên cứu Dược và Thông tin Thuốc, online erschienen am 19.05.2026. Verfasst von Pham Vinh Truong und 3 weiteren Autor:innen.
Themen: Schlaganfall
Abstract (Originalsprache)
Atrial fibrillation (AF) is a common cardiac arrhythmia associated with a substantially increased risk of ischemic stroke and thromboembolic events, imposing a significant clinical and economic burden worldwide. This study aimed to systematically review pharmacoeconomic evaluations of oral anticoagulants, including direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs), in patients with AF, and to explore key determinants influencing cost-effectiveness outcomes. A systematic review was conducted following PRISMA guidelines. Eligible studies were identified from PubMed, the Cochrane Library, and major health technology assessment sources. Data on study characteristics, model structures, costs, health outcomes, and incremental cost-effectiveness ratios (ICER) were extracted and qualitatively synthesized. Reporting quality was assessed using the CHEERS checklist. A total of 27 studies were included. Considerable heterogeneity was observed in model assumptions, perspectives, and cost inputs. Overall, DOACs were associated with higher total costs but yielded greater health benefits, reflected in increased quality-adjusted life years (QALYs) and reduced rates of stroke and major bleeding. Among DOACs, apixaban consistently demonstrated the most favorable cost-effectiveness profile, while dabigatran and rivaroxaban showed variable results across settings. Warfarin remained a cost-effective option in contexts with well-controlled anticoagulation. Cost-effectiveness outcomes were influenced by factors such as healthcare system characteristics, drug prices, analytical perspective, and quality of warfarin management. DOACs are generally cost-effective alternatives to warfarin, particularly in high-income settings; however, their economic value remains highly context-dependent.
Zitieren
APA
Truong, P. V., Van, T. N. K., Duong, V. T., & Mai, K. T. T. (2026). Cost-effectiveness of oral anticoagulants for stroke prevention in atrial fibrillation: a systematic review. Tạp chí Nghiên cứu Dược và Thông tin Thuốc. https://doi.org/10.59882/1859-364x/404
Vancouver
Truong PV, Van TNK, Duong VT, Mai KTT. Cost-effectiveness of oral anticoagulants for stroke prevention in atrial fibrillation: a systematic review. Tạp chí Nghiên cứu Dược và Thông tin Thuốc. 2026. doi:10.59882/1859-364x/404
BibTeX
@article{Truong2026,
author = {Truong, Pham Vinh and Van, Tran Nguyen Khanh and Duong, Vu Thuy and Mai, Kieu Thi Tuyet},
title = {Cost-effectiveness of oral anticoagulants for stroke prevention in atrial fibrillation: a systematic review},
journal = {Tạp chí Nghiên cứu Dược và Thông tin Thuốc},
year = {2026},
doi = {10.59882/1859-364x/404}
}
EUVIMED